Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-301 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the new drug application ("**NDA**") for OT-301 (NCX 470, bimatoprost grenod) as a treatment to lower intraocular pressure ("**IOP**") in patients with open-angle glaucoma or ocular hypertension has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (the "**NMPA**") of the People's Republic of China (the "**PRC**"), supported by data from the Mont Blanc trial and the Denali trial.

The first phase III clinical trial of OT-301 (NCX 470, bimatoprost grenod), namely the Mont Blanc trial, was successfully completed in the United States and China in 2022, in which the primary endpoint showed robust efficacy and safety. Its second phase III clinical trial, namely the Denali trial, is a phase III multi-regional clinical trial evaluating the safety and efficacy of OT-301 (NCX 470, bimatoprost grenod) ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. In August 2025, the Denali trial achieved its primary endpoint of non-inferiority as compared to latanoprost, meeting the efficacy requirements for an NDA in the PRC.

OT-301 (NCX 470, bimatoprost grenod), one of the Group's key drug candidates, is a novel nitric oxide ("**NO**")-donating prostaglandin analog under joint development by Nicox S.A. ("**Nicox**") and the Group. It is a new chemical entity invented by Nicox and designed to release both bimatoprost, a prostaglandin analog approved by the United States Food and Drug Administration, and NO, for the lowering of IOP in patients with open-angle glaucoma and ocular hypertension. The Group obtained an exclusive license from Nicox to develop, make, have made, import, export and sell OT-301 (NCX 470, bimatoprost grenod) in Greater China in December 2018, and extended the exclusive right to Korea and 12 countries in Southeast Asia in March 2020.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-301 (NCX 470, bimatoprost grenod) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 11, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.